Potent small molecule inhibitors of spleen tyrosine kinase (Syk)

被引：74

作者：

Lai, JYQ ^{[1
]}

Cox, PJ ^{[1
]}

Patel, R ^{[1
]}

Sadiq, S ^{[1
]}

Aldous, DJ ^{[1
]}

Thurairatnam, S ^{[1
]}

Smith, K ^{[1
]}

Wheeler, D ^{[1
]}

Jagpal, S ^{[1
]}

Parveen, S ^{[1
]}

Fenton, G ^{[1
]}

Harrison, TKP ^{[1
]}

McCarthy, C ^{[1
]}

Bamborough, P ^{[1
]}

机构：

[1] Aventis Pharmaceut, Bridgewater, NJ 08807 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 18期

关键词：

D O I：

10.1016/S0960-894X(03)00658-9

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of oxindoles demonstrating inhibition of the pbosphorylation of biotinylated substrates of Syk and IgE/FcepsilonRI triggered basophil cell degranulation has been identified. A study of the SAR around sulfonamide 31 (IC50=5 nM, EC50= 1400 nM) is discussed. The modest cellular activity representative of the sulfonamide series was overcome when the Polar surface Area was lowered to < 110 Angstrom(2), leading to the identification of amide 32 (IC50= 145 nM, EC50= 100 nM). (C) 2003 Published by Elsevier Ltd.

引用

页码：3111 / 3114

页数：4

共 50 条

[21] Hematologic toxicities of small molecule tyrosine kinase inhibitors
Nicholas A. Barber
Wais Afzal
Mojtaba Akhtari
Targeted Oncology, 2011, 6 : 203 - 215
[22] Hematologic toxicities of small molecule tyrosine kinase inhibitors
Barber, Nicholas A.
Afzal, Wais
Akhtari, Mojtaba
TARGETED ONCOLOGY, 2011, 6 (04) : 203 - 215
[23] Small-molecule tyrosine kinase inhibitors as radiosensitizers
Lawrence, TS
Nyati, MK
SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (03) : 33 - 36
[24] Small molecule tyrosine kinase inhibitors in pancreatic cancer
Gupta, Sachin
El-Rayes, Bassel F.
BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 707 - 715
[25] Highly potent aminopyridines as Syk kinase inhibitors
Castillo, Marcos
Forns, Pilar
Erra, Montse
Mir, Marta
Lopez, Manel
Maldonado, Monica
Orellana, Adelina
Carreno, Cristina
Ramis, Isabel
Miralpeix, Montserrat
Vidal, Bernat
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (17) : 5419 - 5423
[26] Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP)
Lovering, Frank
Aevazelis, Cristina
Chang, Jeanne
Dehnhardt, Christoph
Fitz, Lori
Han, Seungil
Janz, Kristin
Lee, Julie
Kaila, Neelu
McDonald, Joseph
Moore, William
Moretto, Alessandro
Papaioannou, Nikolaos
Richard, David
Ryan, Mark S.
Wan, Zhao-Kui
Thorarensen, Atli
CHEMMEDCHEM, 2016, 11 (02) : 217 - 233
[27] Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization
Ellis, J. Michael
Altman, Michael D.
Cash, Brandon
Haidle, Andrew M.
Kubiak, Rachel L.
Maddess, Matthew L.
Yan, Youwei
Northrup, Alan B.
ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (12): : 1151 - 1155
[28] A ROLE FOR SPLEEN TYROSINE KINASE (SYK) IN CFTR PROCESSING AND TRAFFICKING
Luz, S. F.
Romeiras, F. M.
Matos, P.
Mendes, A.
Jordan, P.
Amaral, M. D.
Farinha, C. M.
PEDIATRIC PULMONOLOGY, 2009, : 218 - 218
[29] Biochemical characterization of spleen tyrosine kinase (SYK) isoforms in platelets
Singh, Pankaj Kumar
Dangelmaier, Carol A.
Reddy Vari, Hymavathi
Tsygankov, Alexander Y.
Kunapuli, Satya P.
PLATELETS, 2023, 34 (01)
[30] Spleen tyrosine kinase (SYK) inhibitor Hematological cancer therapy
Wei, Zeng-Hui
Koya, Jagadish
Dong, Xing-Duo
Reznik, Sandra E.
Chen, Zhe-Sheng
DRUGS OF THE FUTURE, 2022, 47 (02) : 99 - 107

← 1 2 3 4 5 →